Click here to download a printable version

Wednesday December 1st, 2010

16:00 Registration for the Consensus Conference

20:00 Welcome Aperitif

Thursday December 2nd, 2010

INTRODUCTION

9:00  Principals of the Consensus Conference, PA Clavien

PART I 09:10-12:00

GENERAL CONSIDERATIONS – DIAGNOSTIC, Bruix

09:10 Session A: What is the goal that LT should achieve?

D Samuel, Hepatologist, France
H El-Serag, Hepatologist, USA 
M Colombo, Hepatologist, Italy 
N Heaton, Surgeon, UK

09:50 Session B: Is a tumor biopsy necessary?

B Müllhaupt, Hepatologist, Switzerland
F Durand, Hepatologist, France 
T Roskams, Pathologist, Belgium 
P Dutkowski, Surgeon, Switzerland 
M Heim, Hepatologist, Switzerland

10:30 Coffee Break

10:45 Session C: What is the best staging system of HCC?

K Olthoff, Surgeon, USA
S Hübscher, Pathologist, UK 
A Forner, Hepatologist, Spain 
J Fung, Surgeon, USA

11:25 Session D: What is the optimal imaging modality to stage HCC?

JM Lee, Radiologist, Korea
V Vilgrain, Radiologist, France 
C Wald, Radiologist, USA 
F Trevisani, Hepatologist, Italy

LUNCH 12:00 - 13:30

PART II 13:30-17:45

INDICATIONS OF LIVER TRANSPLANTATION, Lo / Charlton

13:30 Session A:- Milan criteria, where are we?

V Mazzaferro, Surgeon, Italy

14:10 Session B:- What matters: number of tumor, size of larger tumor, total volume of tumor?

AK Burroughs, Hepatologist, UK
G Germani, Hepatologist, UK
K Gurusamy, Surgeon, UK
A Hemming, Surgeon, USA
KS Suh, Surgeon, South Korea
Ch Toso, Surgeon, Switzerland
A Weber, Pathologist, Switzerland

14:50 Session C: Markers for microvascular invasion, where do we stand?

M Kojiro, Pathologist, Japan
S Todo, Surgeon, Japan 
T Ichida, Oncologist, Japan 
C Balabaud, Hepatologist, France
ASH Gouw, Pathologist, Netherlands

15:30 Coffee Break

15:45 Session D:-What information molecular markers may bring?

JM Llovet, Hepatologist, Spain
V Paradis, Pathologist, France 
M Kudo, Hepatologist, Japan 
J Zucman-Rossi, Hepatologist, France

16:25 Session E: What are the criteria for OLT? (Are there extended criteria?)

RB Freeman, Surgeon, USA
SS Zheng, Surgeon, China 
V Mazzaferro, Surgeon, Italy 
KR Prasad, Surgeon, UK 
P Burra, Hepatologist, Italy 
SG Lee, Surgeon, South Korea

17:05 Session F: Should the enlisting criteria be different for HCC in an otherwise normal liver?

J Lerut, Surgeon, Belgium
JA Marrero, Hepatologist, USA 
LC d'Albuquerque, Surgeon, Brazil 
RJ Porte, Surgeon, Netherlands 
D Kahn, Surgeon, South Africa
JN Vauthey, Surgeon, USA

19:30 PRESIDENT DINNER

Friday December 3rd, 2010

PART III  09:00-12:00

BRIDGING THERAPY / DOWNSTAGING / MONITORING ON THE WAITING LIST, Porte / Belghiti

09:00 Session A: Is treatment of HCC on the waiting list necessary?
PE Majno, Surgeon, Switzerland
Impact of TACE: R Poon, Surgeon, Hong Kong
Impact of RF: R Lencioni, Radiologist, Italy
Impact of Surgery: D Cherqui, Surgeon, France 
Impact of Radiotherapy, Chemotherapy and new agents: F Mornex, Oncologist, France

10:00 Coffee Break

10:15 Session B- Does a patient qualify for OLT after downstaging?

F Yao, Hepatologist, USA
C Broelsch, Surgeon, Germany 
S Breitenstein, Surgeon, Switzerland 
M Sherman, Hepatologist, Canada 
JF Dufour, Hepatologist, Switzerland

11:00 Session C- Tools to monitor HCC on the waiting list (αFP, size, biopsy…) and monitoring after liver OLT

N Kneteman, Surgeon, Canada
T Livraghi, Radiologist, Italy
D Madoff, Radiologist, USA 
E de Santibañez, Surgeon, Argentina 
M Kew, Hepatologist, South Africa

LUNCH 12:00 - 13:30

PART IV  13:30-16:00

LIVING DONOR LIVER TRANSPLANTATION, Clavien / Gores

13:30 Session A: Should we use living donor graft for HCC? (ethics considerations)

E Pomfret, Surgeon, USA
M Siegler, Medical Ethics, USA 
P Lodge, Surgeon, UK 
F Villamil, Hepatologist, Argentina

14:15 Session B- Should the LT criteria be different between deceased and living donation?

D Grant, Surgeon, Canada
ST Fan, Surgeon, Hong Kong
G MacCaughan, Hepatologist, Australia 
RA Fisher, Surgeon, USA 
M Abecassis, Surgeon, USA

15:00 Coffee Break

15:15 Session C- Should we use deceased LT after transplant failure from a LDLT?

P Greig, Surgeon, Canada
A d'Alessandro, Surgeon, USA
A Geier, Hepatologist, Switzerland
L Wright, Bioethics, Canada

19:30 GALA DINNER

Saturday December 4th, 2010

PART V  09:00-12:00

TREATMENT AFTER LIVER TRANSPLANTATION, Klintmalm / Hanto

09:00 A- What is the role of adjuvant therapy after LT for HCC?

C Duvoux, Hepatologist, France
B Pestalozzi, Oncologist, Switzerland 
R Miksad, Oncologist, USA
T Kiuchi, Surgeon, Japan 
R Busuttil, Surgeon, USA

09:45 B- What is the impact of immunosuppression on HCC recurrence? Should we adapt it?

JF Trotter, Hepatologist, USA
H Schlitt, Surgeon, Germany 
P Merle, Hepatologist, France 
A Shaked, Surgeon, USA

10:30 Coffee Break

10:45 C- Should patient be retransplanted because of HCC recurrence?

M Schwartz, Surgeon, USA
R Wiesner, Hepatologist, USA 
Y Kita, Surgeon, Japan 
M Rossi, Surgeon, Italy 
JCG Valdecasas, Surgeon, Spain

12:00 - 13:30  LUNCH AND CLOSURE OF THE OFFICIAL PART OF THE CONSENSUS CONFERENCE

Click here to download a printable version